Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.
Also called NCT02831088
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 210 participants
- Sponsor
- Registry
-
NCT02831088
-
- Other papers using this trial's data
- Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02831088. Randomized; triple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2018-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
- Acronym
- SONIC
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Neu2000KWL High-does group
- Intervention (Drug)
- Neu2000KWL Low-does group
- Intervention (Drug)
- Placebo
- Lead sponsor
- GNT Pharma
Record details
- Record id
cardio:ct-nct02831088- Content hash
d77ff4ab4082983fced211ac87f7b1abcbc188819e69b614e9dfd90934fa62ae